effectiveness in combining OrbusNeich's pro-healing cell capture with their fully absorbable drug elution technologies to address the shortcomings with current drug eluting stents (DES), namely the safety concerns associated with the delay and often lack of endothelialization. "In multiple models we have results indicating that this new technology appears to effectively regulate neo-intimal growth, while at the same time promotes the restoration of the arterial wall," explained Granada. These studies highlight the development progress with the next generation of pro-healing drug eluting stent (SES) featuring a combination of endothelial progenitor cell (EPC) capture technology and the abluminal deposition of a fully-absorbable sirolimus eluting matrix.
"Each of these complex technologies on their own offer solutions to the interventionalist," said Seung-Jung Park, MD, PhD, chairperson of the symposium. "By integrating these onto one innovative platform, OrbusNeich is making tremendous strides in being able to offer a single stent addressing multiple concerns."
Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's EPCs to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent, providing a safe and effective alternative to DES.
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Other products in the company's product portfolio are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP, and Lumina(TM).
A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, FL; Hoevelaken, The NethPage: 1 2 3 Related biology technology :1
. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 20082
. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports3
. Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter4
. VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs5
. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated6
. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy7
. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences8
. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile9
. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease10
. RVX-208 Data Demonstrates Increase in Functional HDL Particles11
. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents